COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
World Health Organization (WHO) elevates cholera to highest emergency level due to global resurgence. Crofelemer granted orphan-drug designation by FDA and EMA for cholera treatment -
-
-
COMMUNIQUÉ DE PRESSE
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Jaguar Health, Inc. announces virtual event on crofelemer clinical development efforts for rare diseases MVID and SBS-IF. CEO awarded 'Best CEO BioPharmaceuticals of the Year' -
-
-
COMMUNIQUÉ DE PRESSE
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals presents statistically significant results of crofelemer in breast cancer patients for prophylaxis of CTD at SABCS. Study highlights impact of diarrhea in cancer treatment
